ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2052

Preoperative Timing of Infliximab and Risk of Post-Operative Infection in a Medicare Cohort

Michael D. George1, Joshua F. Baker1, Jesse Yenchih Hsu2, Qufei Wu3, Fenglong Xie4, Lang Chen4, Huifeng Yun5 and Jeffrey Curtis6, 1Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Biostatistics, University of Pennsylvania, Philadelphia, PA, 3Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, 4Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, 6Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Arthroplasty, Biologics, infliximab and surgery, Perioperative management

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Clinical Aspects III: Prevention of Comorbidity

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Patients taking biologic DMARDs often undergo elective surgery, but data to guide if and when to hold biologics before surgery is limited. This study evaluated whether the timing of infliximab before elective hip or knee arthroplasty was associated with an increased risk of serious infection.

Methods: A retrospective cohort study using U.S. Medicare data evaluated adults with rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, or ankylosing spondylitis who received infliximab within 6 months of elective inpatient primary or revision total knee or hip arthroplasty from 2007-2013. Multivariable logistic or Cox regression evaluated associations of infliximab stop time (time between most recent infusion and surgery) with 1) hospitalized infection within 30 days of surgery (excluding urinary infections given relative lack of specificity) using a validated set of discharge diagnoses and 2) rate of prosthetic joint infection (PJI, ICD9 996.66) within 1 year (including within 30 days), adjusting for confounders.  Analyses considering the propensity of being in each stop time category were also performed using inverse probability weighting.

Results: Among 4288 surgeries in 3867 patients, the 30 day cumulative incidence of infection was 6.3% (n = 270), with bacteremia, skin/soft tissue infection, and pneumonia the most common infections. In adjusted analyses, infliximab stop time < 4 weeks vs 8-12 weeks was not associated with an increase in infection within 30 days [OR 0.85, 95% CI 0.58,1.25] [Table]. Risk factors for infection included oral glucocorticoid dose > 10mg, age > 80, higher Charlson comorbidity, previous hospitalized infection, more outpatient visits, and year 2007-2009 (vs 2010-2013) [Table]. Over 12 months, the rate of PJI was 2.9 per 100 person-years (n = 105 infections) and was similar for patients who stopped infliximab < 4 weeks vs ≥ 4 weeks before surgery [Figure]. After adjustment, infliximab stop time of < 4 weeks vs 8-12 weeks was not associated with increased rate of PJI [HR 1.01, 95% CI 0.56, 1.82]. Risk factors for PJI included glucocorticoid use, revision surgery, previous hospitalized infection, extra-articular RA, and year 2007-2009. Results were similar in propensity-adjusted analyses.

Conclusion: Administering infliximab within 4 weeks of elective total knee or hip arthroplasty was not associated with a higher risk of short or long-term serious infection compared to withholding infliximab for longer periods of time. In contrast, glucocorticoid use, especially > 10mg per day, was associated with an increased risk of infection. Table: Results of multivariable logistic regression analysis for serious infection within 30 days, based on 4283 observations among 3863 patients

30 day infection

OR (95% CI)

p-value

Infliximab pre-operative stop time

 

 

  < 4 weeks

0.85 (0.58, 1.25)

0.40

  4-8 weeks

0.90 (0.64, 1.26)

0.53

  8-12 weeks

Reference

–

  12-16 weeks

0.88 (0.47, 1.64)

0.68

  ≥ 16 weeks

1.01 (0.56, 1.83)

0.98

Glucocorticoid dose

  None

Reference

–

  ≤ 5mg/day

1.00 (0.68, 1.47)

0.99

  5-10mg/day

1.15 (0.78, 1.69)

0.49

  > 10mg/day

2.07 (1.29, 3.34)

< 0.01

Non-biologic DMARD use

1.08 (0.83, 1.42)

0.56

Age ≥ 80 years old

1.74 (1.22, 2.48)

< 0.01

Female

1.10 (.080, 1.51)

0.57

Autoimmune Disease

  Rheumatoid Arthritis

Reference

–

  Inflammatory Bowel Disease

1.07 (0.70, 1.64)

0.76

  Psoriatic arthritis/psoriasis/ankylosing spondylitis

0.98 (0.65, 1.47)

0.93

Charlson score, per 1 point increase

1.08 (1.03, 1.12)

< 0.001

Hospitalizations in the past year

  None

Reference

–

  Hospitalization without infection

0.70 (0.48, 1.00)

0.05

  Hospitalization with infection

1.88 (1.27, 2.79)

< 0.01

Outpatient visits in the past year, per visit

1.02 (1.01, 1.03)

< 0.01

Calendar year

  2007-2009

Reference

–

  2010-2013

0.68 (0.52, 0.87)

< 0.01

Region included in the model but not significant with p > 0.05 and not shown. Tested but not included in the final model after step-wise backward selection with p > 0.2 (forcing in age, sex, disease type, glucocorticoid use, traditional DMARD use): race, urban, zip code based median household income quintiles, dual eligibility status, skilled nursing facility stay past year, surgery type, osteonecrosis, extra-articular RA, diabetes, COPD/asthma, kidney disease, obesity, previous biologic therapy, infliximab infusion interval, infliximab dose, antibiotic prescription in the past year


Disclosure: M. D. George, None; J. F. Baker, None; J. Y. Hsu, None; Q. Wu, None; F. Xie, None; L. Chen, None; H. Yun, Amgen, 2; J. Curtis, Roche/Genentech, UCB, Janssen, Corrona, Amgen, Pfizer, BMS, Crescendo, AbbVie, 2,Roche/Genentech, UCB, Janssen, Corrona, Amgen, Pfizer, BMS, Crescendo, AbbVie, 5.

To cite this abstract in AMA style:

George MD, Baker JF, Hsu JY, Wu Q, Xie F, Chen L, Yun H, Curtis J. Preoperative Timing of Infliximab and Risk of Post-Operative Infection in a Medicare Cohort [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/preoperative-timing-of-infliximab-and-risk-of-post-operative-infection-in-a-medicare-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/preoperative-timing-of-infliximab-and-risk-of-post-operative-infection-in-a-medicare-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology